HopeStage
Back to all studies
CompletedNCT05757791

Empagliflozin study for adults with major depression

About this titleRead the official source — NCT05757791

Researchers studied Empagliflozin to find out how it affected depression symptoms in people with depression.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Empagliflozin to find out how it affected depression symptoms in people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 17, 2023
Recruitment status
Completed
Enrollment listed in the registry
20
Sponsor
NYU Langone Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05757791
Official title
Show the full official title

A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Empagliflozin to find out how it affected depression symptoms in people with depression.

Who is behind this study?

The study sponsor is NYU Langone Health.

Did this study involve medication?

Yes. The study involved medication, including Empagliflozin.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies